5Needham Reiterates Buy on Bicycle Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintains a $38 price target.
August 07, 2024 | 10:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Bicycle Therapeutics and maintains a $38 price target.
The reiteration of a Buy rating and the maintenance of a $38 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100